BOTHELL, Wash., July 17 /PRNewswire-FirstCall/ -- Helix BioMedix, Inc.
(HXBM.OB), a developer of bioactive peptides, is providing an update on its
personal care division and the expanded marketing of one of the products
that contains the Company's proprietary HB64 peptide. The Company also
announced the termination of its marketing agreement with Body Blue, Inc.
due to material changes in the Body Blue organization.
Nature's Gate(R) Organics Natural Results(TM) Acne Treatment System,
which includes Helix BioMedix's HB64 peptide, marketed as Oligopeptide-10,
has completed its roll out throughout the Whole Foods Market and Wild Oats
Markets chains and is now being sold in half of the 1000 larger natural
products retail stores in the United States. In addition, Natural
Results(TM) has moved into the mass market where it is initially being sold
in 300 select CVS/pharmacy stores, the largest pharmacy retailer in
America. The product was introduced in the fall of 2005 and is a product of
Levlad Inc., a leading manufacturer and marketer of branded natural and
organic personal care products.
"We are very excited about the continued rollout of Levlad's anti-acne
system," stated R. Stephen Beatty, the Company's President and Chief
Executive Officer. "The product has been well received in the natural
products chains and there are currently plans to expand the product's
distribution further into the much larger food, drug and mass market sector
during the third quarter of 2006."
The company also recently filed an 8-K stating that it has terminated
its marketing agreement with Body Blue, Inc., a privately owned Canadian
company.
"While we have had an excellent relationship with Body Blue, earlier
this month they notified us that they were selling off parts of their
company that are critical to our agreement with them. We are fortunate to
have forged solid relationships with additional marketing partners such as
Grant Industries and thoroughly expect that the consumer product companies
that we have established relationships with, through Body Blue, will
continue to evaluate the use of our peptides in their products," stated Mr.
Beatty.
About Natural Results(TM) Acne Treatment System
Natural Results(TM) Acne Treatment System is a revolutionary,
dermatologist-tested, acne treatment system for use at home. It is the
first acne treatment system of its kind to contain Oligopeptide-10, one of
the latest scientific breakthroughs in acne management. This unique fusion
of 15 naturally occurring amino acids is combined with Salicylic Acid to
form a powerful duo that works synergistically to eliminate bacteria and
combat blemishes. The added benefit of encapsulated Tea Tree Leaf Oil is
particularly beneficial to acne-prone skin and helps to reduce redness for
a clear improvement in the skin's overall condition. For additional
information on Natural Results(TM) Acne Treatment System go to
http://www.Natural-Results.com.
About Helix BioMedix
Helix BioMedix, Inc. is a biopharmaceutical company that has a
portfolio of issued patents that covers six distinct classes of peptides,
including over 100,000 unique peptide sequences. The company's mission is
to become the industry leader in developing and commercializing small
proteins known as bioactive peptides. The antimicrobial and wound healing
properties of these peptides qualify them for inclusion in a wide range of
both pharmaceutical and consumer products. The company is currently focused
on the development of selected peptides as topical anti-infectives and in
wound healing applications. Non-pharmaceutical applications being pursued
by Helix BioMedix include adjuvants for cosmetics/cosmeceuticals, personal
care, plant health, animal health and wide-spectrum biocides. More
information about the company and its proprietary peptides can be found on
the company's website at http://www.helixbiomedix.com.
Important Notice
This press release contains forward-looking statements (statements
which are not historical facts) within the meaning of the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
include statements regarding activities, events or developments that the
company expects, believes or anticipates may occur in the future, including
statements related to our potential growth, product development and
commercialization and revenue. A number of factors could cause actual
results to differ from those indicated in the forward-looking statements,
including the company's ability to successfully raise additional capital,
enter into revenue generating license agreements, continue its research and
development efforts, including pre-clinical and clinical studies, and
general economic conditions. Additional assumptions, risks and
uncertainties are described in detail in our reports and other filings with
the Securities and Exchange Commission. Such filings are available on our
website or at http://www.sec.gov. Readers are cautioned that such forward-looking
statements are not guarantees of future performance and that actual results
or developments may differ materially from those set forth in the
forward-looking statements. The company undertakes no obligation to
publicly update or revise forward-looking statements to reflect subsequent
events or circumstances.
Contact:
Investor Relations:
Cameron Associates
Alison Ziegler 212-554-5469
alison@cameronassoc.com
SOURCE Helix BioMedix, Inc.
 back to top
Related links:
http://www.helixbiomedix.com/
CONTACT:
Investor Relations: Alison Ziegler of Cameron
Associates, +1-212-554-5469 or alison@cameronassoc.com, forHelix
BioMedix, Inc.
|
